Linagliptin

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instanceOf drug
gptkbp:activeDuring linagliptin
gptkbp:approves gptkb:FDA
gptkbp:availability prescription only
gptkbp:brand Tradjenta
gptkbp:chemicalFormula C25H28N8O2S
gptkbp:clinicalTrials Phase III
monotherapy or combination therapy
effective in lowering blood sugar levels
recommended in diabetes treatment guidelines
gptkbp:commonName 5 mg once daily
gptkbp:contraindication allergic reactions
skin reactions
pancreatitis
hypersensitivity to linagliptin
gptkbp:developer gptkb:Boehringer_Ingelheim
gptkbp:dosageForm 5 mg tablet
gptkbp:drugInterdiction tablet
long half-life
antidiabetic agent
increases incretin levels
may increase risk of hypoglycemia
gptkbp:formulation oral medication
film-coated tablet
gptkbp:gestationPeriod B
gptkbp:hasMuseum safety established
gptkbp:healthcare monitor blood sugar regularly
https://www.w3.org/2000/01/rdf-schema#label Linagliptin
gptkbp:interactsWith ACE inhibitors
diuretics
other antidiabetic medications
gptkbp:issuedBy oral tablet
gptkbp:lastProduced 2011
gptkbp:localBusiness widely used worldwide
gptkbp:mandates improving glycemic control
gptkbp:marketedAs multiple countries
gptkbp:nutritionalValue primarily in the liver
gptkbp:offers varies by region
gptkbp:patentExpiration 2026
gptkbp:personalLife diet and exercise important
gptkbp:researchAreas diabetes management
gptkbp:researchInterest ongoing studies for cardiovascular outcomes
gptkbp:safetyFeatures generally well tolerated
gptkbp:sells Tradjenta
gptkbp:sideEffect headache
diarrhea
hypoglycemia
nasopharyngitis
gptkbp:supplyChain manufactured_by_Boehringer_Ingelheim
gptkbp:targets adults with type 2 diabetes
gptkbp:triggerType DPP-4 inhibitor
gptkbp:usedFor type 2 diabetes
gptkbp:variant insulin
metformin
sulfonylureas
gptkbp:waterManagement urine